SY11-4 Non-clinical patient-derived models for co-clinical trial

Abstract

Several non-clinical patient-derived models are used for anticancer drug development. In vitro cell killing assays using commercially available cell lines or in vivo tumor growth inhibition assays using cell-line-derived xenograft (CDX) models, in which these cell lines are transplanted into immunocompromised mice, are commonly employed to measure the efficacy of anticancer drugs. Unfortunately, few drugs are approved even if the drugs demonstrate a good response in these preclinical studies. To overcome this issue, patient-derived xenograft (PDX) models, in which patient-derived cancer tissues are directly transplanted into immunocompromised mice, are used and recognized as accurate and clinically relevant models.